Nitrofurantoin

• Uncomplicated urinary tract infections (uUTIs) lead to substantially higher healthcare costs, with patients incurring over £1200 in annual healthcare expenses compared to £460 for matched controls. • Treatment failure in uUTIs creates economic burden through additional healthcare visits, repeated diagnostic tests, and rescue medications, while potentially leading to serious complications like pyelonephritis and sepsis. • A large-scale study of 120,519 female patients in England found that 0.2% required hospitalization during their uUTI episode, with key risk factors including older age and prior hospital admissions.

• The FDA has approved gepotidacin (Blujepa), the first new class of oral antibiotics for urinary tract infections in nearly 30 years, addressing growing concerns about antimicrobial resistance. • Developed by GSK with partial funding from US government agencies, Blujepa works by interfering with bacterial enzymes needed for replication, potentially reducing the likelihood of resistance development. • Clinical trials involving over 3,000 females demonstrated Blujepa's efficacy comparable to or better than nitrofurantoin, with availability expected in the second half of 2025.

GSK's Blujepa (gepotidacin) has received FDA approval for treating uncomplicated urinary tract infections, marking the first new class of oral antibiotics for UTIs in nearly three decades.

Gepotidacin represents the first potential new oral antibiotic for urinary tract infections in over 20 years, offering a novel mechanism that overcomes fluoroquinolone resistance.

The FDA has granted priority review to GSK's new drug application for gepotidacin, an oral antibiotic for uncomplicated urinary tract infections (uUTIs).